https://www.selleckchem.com/pr....oducts/alizarin-red-
34 [95% confidence interval [CI], 0.22-0.52), p 0.01) and lower adjusted neurological complications (OR, 0.68 (95% CI, 0.54-0.85], p 0.01). On adjusted analysis, 30-day all-cause readmissions (Hazard ratio, HR 0.839, [95% CI, 0.773-0.911], p 0.01) and stroke (HR, 0.727 [95% CI, 0.554-0.955), p=0.02) were less likely in TAVR with CPD. We report real-world data on utilization and in-hospital outcomes of CPD use in TAVR. CPD use is associated with lower inpatient mortality, neurological, and clinical complications as
Like
Comment
Share
